Factors determining short term graft function in Renal Transplant Recipients. by Jayalakshmi, S
 
FACTORS DETERMINING SHORT TERM GRAFT 
FUNCTION IN RENAL TRANSPLANT RECIPIENTS 
 
 
 
 
 
Dissertation Submitted for  
 
 
D.M. DEGREE EXAMINATION  
BRANCH NO.III, NEPHROLOGY 
DEPARTMENTAL OF NEPHROLOGY 
MADRAS MEDICAL COLLEGE 
CHENNAI - 600 003. 
 
 
 
 
 
 
 
 
 
 
 
 
THE TAMIL NADU  
DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI - TAMILNADU 
 
 
AUGUST 2008 
 
CERTIFICATE 
 
 
 
This is to certify that this dissertation entitled FACTORS 
DETERMINING SHORT TERM GRAFT FUNCTION IN RENAL 
TRANSPLANT RECIPIENTS submitted by Dr. S.Jayalakshmi, appearing for 
the D.M., Nephrology Degree Examination in August 2008 is a bonafide 
record of work done by her under my direct audience and supervision in 
partial fulfillment of regulations of the Tamilnadu Dr. M.G.R. Medical 
University, Chennai, Tamilnadu, India. 
 
 
 
Prof.Dr.M.JAYAKUMAR, M.D.,D.M.,           
Professor and Head,      Dean, 
Department of Nephrology, Madras Medical College  
and       
Madras Medical College and        Research Institute  
Research Institute,            Government General Hospital 
Government General Hospital              Chennai - 600 003   
Chennai - 600 003. 
 
 
 
 
ACKNOWLEDGEMENT 
 
 
 I would like to express my sincere gratitude to my beloved Professor 
and  Head of Nephrology Department, Professor. M.Jayakumar, for his 
motivation, advice, guidance and constructive criticism which enabled the 
completion of this work. 
 
 I am extremely grateful to my Assistant Professors Dr.M.Edwin 
Fernando, M.D. D.M.,  Dr. R. Manorajan  M.D. D.M.,  Dr. V. Balaraman  
M.D  D.M. and   Dr. T. Balasubramaniyan M.D.D.M. for their valuable 
guidance and co-operation. 
 
 My sincere thanks to the staff and technicians of the Nephrology 
Department and Renal Transplantation Unit for their co-operation. 
 
I thank Mr.A. Vengadesan Statistician of the Central Epidemiological 
Unit for the statistical guidance rendered. 
 
  I am immensely thankful to the patients who participated in this 
study.  
CONTENTS 
Sl. 
No. 
Particulars Page No. 
1. Introduction  1 
2. Review of Literature 3 
3. Objectives of the Study 19 
4. Renal Transplantation in our Institution 20 
5. Materials and Methods 23 
6. Exclusion Criteria 26 
7. Results 27 
8. Discussion 44 
9. Conclusion 52 
10. Limitations 53 
11. Statistical Methods 54 
12. Definitions  55 
13. Bibliography  
14. Annexures   
 
 
 1
INTRODUCTION 
The first successful kidney transplants in humans were from identical 
twin living donors. Although transplanted before the development of 
chemical immunosuppression, many of these identical twin grafts had 
long-term survival. With recognition of the immunosuppressive effects of 
prednisone and azathioprine, the use of non twin donors became possible. 
Considerable controversy soon followed as to whether it was ethical to 
use living donors for kidney transplantation. Proponents of the use of 
living donors noted that the short and long-term patient and graft survival 
rates were better after living (vs. cadaver) donor transplants. Opponents 
worried that living donor nephrectomy was a major operation with 
potential risk to the donor; they believed that these risks did not justify 
the benefits to the recipient 1. 
 The biggest challenge in transplantation today is increasing 
the number of available organs. However, in the past 2 years, the number 
of living donor transplants in the United States has increased. Much of 
this increase followed the recognition that living unrelated donor 
recipients had out-comes similar to those of living related non-HLA-
identical donor recipients 1. 
 2
 A number of recent analyses demonstrate the importance of 
events early post-renal transplantation in determining long-term allograft 
outcomes. In particular, worse long-term outcomes are associated with 
delayed graft function (DGF), irrespective of the occurrence of acute 
rejection2. Attempts have therefore been made to improve early graft 
function by a variety of mechanical, pharmacological and organ 
allocation strategies. If suboptimal early graft function could be 
accurately predicated, the success of these strategies may be improved3. 
 The serum creatinine at 1 year, rather that the serum creatinine 
at 3 or 6 months, was found from this analysis to be an excellent predictor 
of the long-term survival of the graft as was reported by Hariharan. It was 
also found to be an important factor in a recent report by He and 
Johnston. With this background, we wanted to analyse the factors that 
improve short term graft survival4.   
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REVIEW OF LITERATURE 
 The living donor transplantation offers a lot of advantages in 
terms of graft survival. Ischaemia time and presence of Hypotension / 
ATN in donor are important determinants of graft survival in cadaver 
transplants. Living donor transplants are virtually devoid of these 
adversities and hence we undertake the study to evaluate factors that 
determine short term graft survival in living donor transplants.  The 
outcome has significantly improved for both cadaver and living donor 
recipients, but living donor recipients continue to have better long-term 
patient and graft survival rates (Vs. cadaver donor recipients). 
  This better outcome was originally attributed to genetic 
matching; in the past, almost all living donors were relatives. However, 
many recent studies have noted that living unrelated donor recipients 
have outcomes similar to those of non-HLA-identical living related donor 
recipients. Thus, the major advantages of living donor transplants are 
likely due to the process itself; the ability to evaluate the donor fully, the 
opportunity to schedule surgery electively when both donor and recipient 
are in optimal condition, and the minimal ischemic time such that DGF is 
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relatively rare. In fact, the subset of cadaver donor recipients with 
excellent immediate post-transplant function have outcomes similar to 
living donor recipients5. 
 Receiving a living (vs. cadaver) donor kidney is a significant 
advantage. Both short and long-term results are better. A disadvantage of 
living donation is that donors undergo a major operation that they do not 
need. Clearly, donors are not better off with one kidney rather than two. 
However, considerable data support the concept that an individual with 
one normal kidney can lead a normal life6: children born with one normal 
kidney live a normal life; children or adolescents who have a kidney 
removed because of a tumor or trauma live a normal life (if the remaining 
kidney is normal); and donors followed up for 20 to 30 years do not have 
an increased incidence of kidney disease compared with their brothers 
and sisters who did not donate.7. Kidney donors do not have trouble 
getting life insurance, and insurance rates are not increased after 
donation. Although donation carries no physical benefit, studies have 
shown a psychological benefit: an increase in self-esteem.8 In addition, 
donor evaluation has revealed previously unrecognised and treatable 
medical problems. 
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 The biggest challenge in transplantation today is increasing 
the number of available organs. Although the outcome after living donor 
transplantation is better than after cadaver donor transplantation, the 
number of living donor kidney transplants done annually was unchanged 
for years because of the reluctance of transplant personnel to put a 
potential donor through a major and unnecessary operation. However, 
because of the rapidly growing waiting list for cadaver transplants and the 
increasingly longer wait, most centers are now willing to advocate living 
donation. In the past 2 years, the number of living donor transplants in the 
United States has increased. Much of this increase followed the 
recognition that living unrelated donor recipients had outcomes similar to 
those of living related non-HLA-identical donor recipients. 
 Many studies have attempted to identify the risk factors for 
chronic allograft nephropathy. Most have identified donor related factors 
such as age and function, and immunologic factors, which are strongly 
associated with previous acute rejection episodes, as the most important. 
The effects of potentially nephrotoxic immunosuppressive agents such as 
calcineurin inhibitors are still widely debated, although there is general 
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agreement that high levels, even within the first year may pose a threat to 
long-term function. It is likely that both the etiology of chromic allograft 
nephropathy and its evolution represent the summation and interaction of 
multiple variables9. 
 For recipients with at least 1-year graft survival, they noted 
several significant risk factors for worse long-term outcome. Those with 
pre-transplant cardiac or peripheral vascular disease and those who 
smoked before the transplant had worse graft survival. Cosio et al10 
recently showed a dramatic decrease in post-transplant patient survival 
rates in recipients who smoked before the transplant. What can be done to 
improve the outcome for such recipients? First, those with pre-transplant 
cardiac or peripheral vascular disease should be aggressively screened to 
identify any treatable cardiac lesions. If lesions are identified, they should 
be treated before the transplant. Such an approach has decreased the post-
transplant death rate in diabetic transplant recipients. Second, for 
candidates waiting for a transplant, hyperlipidemia and hypertension 
should be aggressively managed. Third, if there is a long interval (>1 
year) between initial evaluation and the transplant, candidates should 
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undergo re-evaluation.11 Finally, all transplant candidates should be 
strongly encouraged to stop smoking. 
 
 The main determinant of 1 year graft survival in the series by 
Isahl et al, after censoring for death with a functioning graft, was DGF. 
There were no adverse effects of other donor factors including donor age 
or ICU management on 1 year graft survival. Importantly, no other 
factors were significant, including AR, HLA matching, highly sensitized 
recipients and re-graft. The lack of an effect of AR on 1 year graft 
survival is surprising but not unexpected. This phenomenon has been 
mirrored in many recent publications comparing immunosuppressive 
regiments. It would suggest that AR in the first year is no longer a good 
endpoint for comparative studies12. 
 In a study done by Steven et al, Five year graft survival for 12 
months Cr level less than 1 (n=38) was 95% for 1.0 to 1.4 (n=454) 87%; 
for 1.5 to 1.9 (n=463), 86%; for 2.0 to 2.4 (n=166), 78%; for 2.5 to 2.9 
(n=54), 60%; for greater than or equal to 3 (n=45), 41%. A major 
breakpoint for outcome is 1 year Cr level = 2.0. A power analysis was 
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performed for the combined endpoint of graft loss and 1 year Cr level 
greater than 2, reached by 30% of patients13. 
 The 12 month serum Cr level was the most powerful predictor 
of long-term graft failure. Based on this finding, they selected a serum Cr 
level of 2.0 mg/dL as the point beyond which an excessive decline in 6 
and 10 year graft survival was seen. Of recipients with 12 month serum 
Cr level greater than 2.0 mg/dL 50% lost their graft within 10 years, 
whereas graft survival was more than 65% at 10 years for those with a 12 
month serum Cr level less than 2.0 mg/dL13. 
 In a recent publication, Meier-Kriesche and colleagues14  have 
reported a strong association between renal function at 1 year and the risk 
of cardiovascular disease and infectious mortality. According to this 
publication, a serum creatinine level of 1.9 - 2.1 mg/dl. Conferred a 50% 
increased risk of cardiovascular death compared with a serum creatiuine 
level of < 1.3 mg / dl.   
 The only factors affecting the long-term survival of those 
grafts that reached 1 year after censoring for death were recipient age and 
CIT and no apparent effect of AR or HLA matching. Crucially, it was 
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found in a study by Isahel et al that CIT affects long-term graft survival 
independently of the phenomenon of DGF. Other studies have found that 
DGF is one of the most important factors related to graft loss but have not 
identified CIT as having an impact in the long-term. In contrast, Ojo and 
colleagues in a study from American registry data found that pro-longed 
CIT directly and independently of DGF and AR, compromised the long-
term graft survival. In this study, it was shown that the effect of CIT on 
long-term graft survival is linear and hence, there is no threshold below 
which CIT is acceptable or a threshold beyond which the deleterious 
affect of CIT accelerates15. 
 The serum creatinine at 1 year, rather that the serum creatinine 
at 3 or 6 months, was found from this analysis to be an excellent predictor 
of the long-term survival of the graft as was reported by Hariharan16. It 
was also found to be an important factor in a recent report by He and 
Johnston17. 
 Moreso et al have shown that patients receiving a kidney form  
old donors who suffer from DGF have a very poor long-term graft 
survival even in rejection free patients. These data indirectly support the 
suggestion that the deleterious effect of DGF on late graft outcome is 
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amplified in patients receiving a kidney harvested from an old donor. 
Consequently it seems reasonable to control those factors associated with 
DGF such as cold ischaemia time or cyclosporine nephrotoxicity in order 
to improve long-term results when organs from elderly donors are 
accepted for transplantation18. 
 Female donor gender and higher recipient/donor weight ratio 
are major predictive factors in the development of DGF following living-
related kidney transplantation. Although DGF alone did not affect the 
outcome, long-term graft survival was significantly reduced when DGF 
was associated with acute rejection episodes19.  
 During the first year post-transplant, the benefits of receiving 
a living donor kidney (versus a cadaver kidney) mitigate negative 
cofactor risks of graft failure. Beyond one year, recipients of living donor 
kidneys are subjected to the same deleterious effects from cofactors and 
early post-transplant events that impact the long-term graft survival 
following cadaveric transplantation20.  
 In a Study by Nishikawa and Terasaki, using univariate 
analysis, it was shown that graft survival kidneys from older living 
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donors was significantly better than that of kidneys from older cadaver 
donors and was comparable to that of kidneys from younger cadaver 
donors. Using multivariate analysis, it was shown that the presence of one 
or more acute rejection episodes significantly shortens both cadaver and 
living donor long-term graft survival. Although the use of kidneys from 
cadaver donors >55 years was associated with significantly decreased 
long-term graft survival, no such association exists for recipients of 
kidneys from living donors >55 years.   
 Cold ischaemia has been shown to be especially damaging 
when the transplantation is performed with a kidney from an elderly 
donor; DGF appears in over 40% of transplant patients when its cold 
ischaemia is over 24 h. On the other hand, we do not know the 
physiopathological mechanism that could explain the relationship 
between the type of dialysis followed by the uraemia patient and DGF21. 
In our study we could not study the effect of the type of dialysis since all 
our patients underwent only hemodisalysis. 
 In the group of patients studied by Ricard et al the presence of 
DGF in itself only negatively influenced graft survival, after censoring 
for death, when the kidney came from an elderly donor. However, 
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considering any kind of donor, they were able to relate DGF to acute 
rejection and kidney dysfunction, which did demonstrate their negative 
influence on patient and graft survival. Thus, they detected a greater 
incidence of acute rejection in the patients that presented with DGF. The 
mechanism by which DGF and acute rejection are associated has not been 
completely clarified, but a greater expression of MHC is invoked in the 
kidneys that suffered from a period of ischaemia, which would more 
easily provoke the immunological response of the recipient22. 
 In a study at Netherlands by Henk Brom et al, several risk 
factors for DGF were identified, of which a low recipient pre-transplant 
mean arterial blood pressure, the transplantation of kidneys from female 
donors to male recipients, and a prolonged cold ischemia time were 
potentially avoidable. Although DGF is one of the several risk factors of 
acute rejection and suboptimal function at one year, it is not 
independently associated with an increased rate of graft loss23. 
 In a univariate analysis; DGF was correlated with graft loss 
within the first year, as were female donor gender, an Aza-based 
immunosuppressive regimen, CIT of more than 24 hours, and the number 
and type of rejection episodes. Sharing of HLA class-1 antigens 
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correlated inversely with graft loss. However, when the data were entered 
in a multivariate analysis, neither DGF nor cold ischemic time remained a 
risk factor for graft-loss within the first year. Acute rejection episodes, 
especially vascular rejection female donor gender and an Aza-based 
immunosuppressive regimen remained independently associated with 
graft loss within the first year23. 
 
 Higher grade HLA mismatch has previously been reported to 
be associated with an increased risk of DGF. Terasaki et al recently 
showed that graft survival in cadaveric transplants with immediate 
function is superior to that in zero-HLA mismatched transplants 
compromised by DGF. The current study by Akinlolu et al showed that 
zero-mismatched kidneys yielded better graft survival within each 
category of graft function, but on a comparative basis, the modest benefit 
of HLA matching is smaller than that early graft function. Thus, it may be 
better to received a “fresh” kidney than a well-matched one24. 
 How can DGF, independent of early acute rejection, 
negatively effect renal allograft survival? First, severe acute tubular 
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necrosis may be associated with actual nephron destruction. The 
development of severe acute tubular necrosis may be further exacerbated 
by either cytokine-releasing induction therapy and / or cyclosporine 
therapy if cyclosporine is used before graft function is established. This 
early pruning of renal nephron mass may predispose to hyperfiltration 
injury of the remaining nephron mass of the allograft 25, DGF may be 
associated with a rich tubular-interstitial milieu of proximal 
proinflammatory agonists, including interferon-γ, interleukin 2, 
transforming growth factor - β, and interleukin 4 which may stimulate 
non-antigen-dependent inflammation and scarring. 
 That DGF is an independent risk factor for long and short-
term graft survival is in contract to the results of a single-center study in 
which DGF was associated with acute rejection episodes, but was not a 
significant risk factor for diminished 5 year graft survival26. 
 The influence of demographic characteristics (age, sex race); 
transplant variables (cadaver versus living donor, cold ischemia time, 
HLA mismatching, delayed graft function and transplant year), and post-
transplant variables (immunosuppressive agents for the prevention of 
acute rejection, clinical acute rejection and post-transplant renal function 
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in the first year) on graft survival were analyzed for 105,742 adult renal 
transplant between 1988 and 1998. 
 In conclusion, it was found that one year creatinine and ∆ 
creatinine values predict long-term renal graft survival. Recent 
improvements in graft half-life are related to conservation of renal 
function within the first year post-transplantation27. 
 In previous studies, discharge creatinine was identified as a 
strong predictor of transplant survival. The projected median graft half-
life for cadaveric transplants with discharge creatinine values of 0.5 to 1.5 
mg/dL was 11.5 years. Half-life values for patients with discharge serum 
creatinine 1.6 to 2.5 ad >2.5 mg/dl were 9.6 and 7.2 years, respectively. 
But discharge creatinine has limited value as many patients are 
discharged within a few days after transplant, before they reach nadir 
creatinine levels. This is true especially for recipients of renal transplants 
from older donors, those with prolonged cold ischemia time and those 
who experience DGF. One month creatinine values may be falsely 
elevated due to higher cyclosporine and tacrolimus levels used to prevent 
acute rejection. Hence, the study by Hariharan et al, used six month and 
one year creatinine values to predict long-term graft survival27. 
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 This study illustrates that event occurring within the first year 
are of critical importance for long-term graft survival. Thus, the quality of 
renal function at 1 year  should be implemented as a newer endpoint for 
primary comparative trials. 
 In a study by Xiang He et al seven independent risk factors for 
allograft failure were identified; older recipient, male recipient and 
younger donor above average creatinine chronic allograft nephropathy, 
diabetic recipient, and neoplasm after transplant. 
 Among these seven independent risk factors were found to 
influence graft survival, only two of these could be modified by clinical 
intervention, elevated serum creatinine at 1 year and the occurrence of 
chronic allograft nephropathy. To influence these two factors, the 
optimization of immunosuppressive therapy is essential29. 
 CAN (previously often referred to as chronic allograft 
rejection) is the most important cause of transplant recipients returning to 
dialysis after a renal transplant. This study confirms that CAN is the main 
risk factor for graft failure the first year transplantation. Recipients with 
CAN demonstrated a seven times higher risk of losing their graft 
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compared with recipients without CAN. Only 70% of patients with CAN 
still had a surviving graft 7 years post-transplant compared wit h95% of 
patients free of CAN. 
 This study confirmed that a higher than average serum 
creatinine level (i.e., >162 μmol/L) at 1 year post-transplant was linked to 
poor graft survival. Non immunologic factors of both donor and recipient 
variables have been widely discussed as risk factors for long-term graft 
survival. The recipient variables (age, body mass index, sex, history of 
dialysis) and the donor variables (age, sex cadaveric donor, HLA 
mismatch, and cold/first warm ischemia time) have all been reported to 
affect graft survival. In the present study, male recipients had more than 
twice the risk of demonstrating graft failure than female recipients. 
Regardless of the different sex combinations of donor and recipient 
(M/M, M/F, and F/M), female recipients always demonstrated better 
survival rates than males (ρ < 0.001). 
 Concomitant illnesses have also been shown in previous 
studies to be risk factors for allograft failure, for example, diabetic 
recipients have been shown to have a higher risk of graft failure than non-
diabetic recipients. This study confirmed that patients with pre-existing 
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diabetes mellitus demonstrated more than twice the risk of losing their 
graft than patients without existing disease. However, for those patients 
who developed diabetes after transplantation, graft survival was not 
significantly reduced by the onset of the disease. This may, in some part, 
be because of the quality and frequency of care they receive post-
transplantation. 
 Therefore going though the literature, it is evident that events 
occurring in the first year of transplant influence graft survival. The S 
creatinine at 12 month post transplant has been found to be a significant 
factor determining long term graft survival. 
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OBJECTIVES OF THE STUDY 
To determine the factors that influence graft functioning at 1 year in live 
related Donor Renal Transplant. 
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RENAL TRANSPLANTATION IN OUR INSTITUTION 
1. Donors: 
In our institution, we have so far done 750 Renal Transplantations Only 
first degree related persons are taken as Donors for renal transplantation. 
After enquiring the family details, a HLA matching is done. If there is n 
match, then Approval by Authorisation committee is obtained before 
transplantation. 
At a point of time when kits for HLA matching were not available, the 
Patients, and Donors were sent to committee only for ascertaining the 
Relationship.  
In our institution the criteria for a Donor is 
(i) The person should be more than 20 years and less than 60 years of 
age. 
(ii) The person should either parent sitting or offspring of the patient. 
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(iii) Spousal Donors are considered provided there is a valid evidence of 
marriage and when there are no eligible/willing first degree related 
donors. 
Complete evaluations of the Donors are done to R/O any undetected / 
underlying disease / condition. The Donor should be of perfect health 
prior to being declared fit for transplantation. 
Donor GFR is done using 24 hour urine creatinine estimation. Donors 
with a Cr cl < 70 ml / minute are rejected.  
Donors are tested routinely for Hepatitis Viral serology and HIV ELISA. 
CMV screening is not done routinely. 
Donors are explained in detail about the procedure of transplantations and 
possible risk even if remote of subsequent Development of Renal 
Insufficiency. 
A written informed consent is obtained from the Donor and the spouse  
 22
 
2. Recipient: 
Recipient can be of any age. The recipient is initially evaluated fully. The 
cause of CKD is ascertained in as many cases as possible. If the patient 
has a kidney size amenable to Biopsy a tissue diagnosis is obtained. 
 
All recipients undergo viral serology testing. They undergo complete 
cardiac / gastroenterology / ENT / Dental and dermatological evaluation. 
All patients are given 3 doses of Double dose HBV vaccination. 
Any forms of sepsis are treated before the transplantation procedure.  
A voiding cystourethrogram is done for all patients to exclude lower 
urine tract anomalies. 
All patients are maintained only on Haemodialysis prior to 
transplantation. 
All patients are given triple immunosuppression with cyclosporine, 
azathioprine and prednisolone. 
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MATERIALS AND METHODS 
This is a retrospective study.  
The patients who underwent Live Donor Renal Transplantation between 
March 2005 to February 2007 were taken for study. 
Demographic data such as Name, Age gender of both Donor and 
Recipient were recorded. 
The other variables taken were for the Recipient.  
Native Kidney Disease 
Blood group 
   HLA typing 
   Cardiac / Respiratory status. 
         Presence/Absence of  
       Diabetes Mellitus  
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For the Donor  : Relationship 
            GFR 
            HLA typing 
            Blood group 
Common Parameters   :        Gross matching. 
Intra Operative and Post operative data :  
Intra operative Hypotension 
        Cold Ischaemia Time  
        Warm Ischaemia Time 
        I day urine output 
        I day S-creatinine  
                              Time to Normal creatinine  
                                   Discharge creatinine  
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               Creatinine during 3, 6 & 12 months.  
              Events during I year  
             AR / GDF /Infections  
            Biopsy of Allograft if done 
All the data were fed into a master chart and statistical analysis were 
done. 
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EXCLUSION CRITERIA 
 
All the patients who did not survive beyond the first year of transplant 
were not included in the study. 
 
The patient who underwent graft nephrectomy for graft artery thrombosis 
was not included.  
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RESULTS 
 
Demographic Data: 
Totally 89 Renal transplantations all live related Donor transplantations 
took place from March 2005 to February 2007. 
 
Patients among them died within the first year and were not included. 
One person underwent graft nephrectomy due to graft artery thrombosis. 
After excluding 10 such patients, 79 patients were included in the study. 
 
The Recipients age ranged from 13 years to 51 years. The mean age of 
the Recipients was 28.58 ± 8.59 years. 
 
The Donors’ age ranged from 24 years to 58 years. The mean age was 
44.5 ± 7.81 years. 
 
Among the recipients, there were 68 males. There were only 14 males 
among the Donors. Recipients were predominantly male and Donors were 
mostly Females. 
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Age Distribution: Recipient 
 
 Mean 28.58 Yrs. 
 S.D. 8.59 Yrs. 
Min 13 Yrs 
Max 51 Yrs. 
 
 
 
 
Donor Age Distribution: 
 
Mean 44.5 Yrs. 
S.D. 7.81 Yrs. 
Min 24 Yrs 
Max 58 Yrs. 
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Recipient – Gender Distribution: 
 
Particular No. % 
Male 68 86.1 
Female 11 13.9 
Total 79 100 
 
 
 
Donor – Gender Distribution: 
 
Particular No. % 
Male 14 17.7 
Female 65 82.3 
Total 79 100 
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The native kidney diseases in the transplanted patients were as follows 
Native Kidney Disease: 
 
Particular No. % 
Diab Neph. 1 1.3 
CGN 20 25.2 
RPGN 1 1.3 
FSGS 2 2.5 
DPGN 1 1.3 
PUV 2 2.5 
CIN 1 1.3 
IGAN 6 7.5 
Obs. Neph 2 2.5 
N/K 43 54.4 
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The nature of HLA matching were as follows: 
 
HLA Matching: 
 
Type Frequency % 
Nil 0 0 
Haplo 60 75.8 
Full House 3 3.8 
ND 16 20.4 
 
HLA matching could not be done for 16 patients/donors since the kit was 
not available at that time. 
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OUT COMES 
 
Events during the first year were as follows: 
 
  No % 
None 43 54.4 
AR 13 16.3 
GDF-CNI 2 2.5 
GDF-CMV 4 5.2 
GDF-CAN 4 5.2 
GDF-UTI 3 3.8 
GDF - uncl. 10 12.6 
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Graft Function at 1 year: 
 
S. Creat Frequency % 
< 106 μmol/L 21 26.6 
107 to 176 38 58.1 
> 176 20 25.3 
 
One year graft function with respect to the following variables were 
analysed: 
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Graft Function with respect to: 
Donor Age: 
 
Age  in years S Creat ≤ 176 S. Creat > 176 Total 
20 - 30 39 13 52 
31 - 40 12 5 17 
41 - 50 7 2 9 
51 - 60 1 -- 1 
Total 59 20 79 
 
P value < 0.05 significant 
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Donor GFR: 
 
GFR ml/min S cr ≤ 176 S cr > 176 Total 
70 – 80 7 8 15 
81 – 90 20 3 23 
91 – 100 16 3 19 
> 100 16 6 22 
Total 59 20 79 
 
Donor GFR was found to be a significant variable. 
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Cold Ischaemia Time: 
 
CIT (min) S cr ≤ 176 S cr > 176 Total 
< 30 3 -- 3 
31 - 40 29 10 39 
41 - 50 21 7 28 
> 50 6 3 9 
Total 59 20 79 
 
P value not significant 
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Inta Operative Hypotension: 
 
 
I O Hypotension S cr  ≤ 176  S cr  > 176 Total 
Nil 52 14 66 
Present 7 6 13 
Total 59 20 79 
 
Χ2 = 3.84 
P = 0.05 - significant 
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I day Urine Output: 
 
I day Output (ml) S cr ≤ 176 S.cr > 176 Total 
< 4000 3 3 6 
4000 - 6000 7 2 9 
6000 - 8000 10 2 12 
8000 - 10000 17 2 19 
> 10000 22 11 33 
Total 59 20 79 
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Time to (N) Creatinine: 
 
Duration (Days) S cr ≤ 176 S. cr > 176 Total 
< 3 days 25 6 31 
3 - 7 days 19 7 26 
> 7 days 15 7 22 
Total 59 20 79 
 
P value not significant. 
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Discharge Creatinine: 
 
Disch. S.Creat 
(μmol/L) 
1 year S Creat ≤ 
176 
1 year  S. 
Creat > 176 
Total 
< 88 21 4 25 
89 - 106 29 4 33 
> 106 9 12 21 
Total 59 20 79 
 
Χ2 = 15.44 
P = 0.001 – significant 
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Analysis of variables influencing the S.Creat at 1 year: 
 
Mean creatinine with respect to events in the first year: 
 
Events in I year No. Mean S Creat SD 
None 43 115.20 22.385 
AR 13 273.80 82.561 
GDF-CNI 2 237.00 4.243 
GDF-CMV 4 180.75 48.083 
GDF-CAN 4 334.00 137.179 
GDF-UTI 3 191.00 74.246 
GDF - uncl. 10 213.60 104.858 
 
Oneway Anova – Analysis of variance 
F = 8.74 
  P = 0.001 - significant 
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Factors influencing graft function at 1 year 
 
Donor Age and Discharge creatinine influenced graft fn at 1 year 
significantly.  
 
Factors S cr ≤ 176 S. cr > 176 P 
Value 
 Mean SD Mean SD  
Age of rec. 28.27 9.1 29.50 6.8 0.58 
Donor Age 43.12 7.4 48.75 7.7 0.001 
CIT 43.66 8.6 45.25 6.4 0.47 
I day output 92.08 3364 9736 4487 0.58 
Time to N 
creat 
5.58 4.2 5.84 3.9 0.88 
Dis Creatin 100.44 20.6 131.40 66.8 0.002 
Donor GFR 92.90 12.1 90.20 14.1 0.47 
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Multivariate Analysis by Cox Regression Model. 
 
 
Factors B SE Wald Df Sig Exp (B) 
Donor Age - .048 .016 8.506 1 .004 .953 
Donor GFR .005 .011 .191 1 .662 1.005 
Hypotension .502 .409 1.504 1 .220 1.652 
Dis. Creat - .047 .183 .067 1 .796 .954 
 
 
By multivariate analysis Donor age was the most significant factor 
influencing graft function at 1 year. 
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DISCUSSION 
 
Among the 89 Renal transplantations done during the study period, 79 
were taken for the study. Ten patients were not included one person had a 
steroid resistant rejection,  never regained graft function and died due to 
Sepsis; one person had respiratory failure secondary to status epilepticus. 
One patient had a graft artery rupture; five patients died due to fulminant 
sepsis; one patient with ADPKD had graft artery stenosis with partial 
recanalisation and subsequently succumbed to sepsis. The tenth patient 
had graft nephrectomy for graft artery thrombosis and returned to 
dialysis. 
The patients old records were analysed to study the nature of the native 
kidney disease. The native kidney disease could not be found out in 43 
out of 79 patients included in the study. 
There were two patients with type 2 diabetes Mellitus. One of them had 
Diabetic Nephropathy leading to chrome Kidney Disease. The other 
person presented with no proteinuria and contracted kidneys and 
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therefore a diagnosis non diabetic kidney disease was diagnosed in that 
patient. 
Two patients had Posterior Urethral values which was diagnosed in 
childhood and treated but patients later progressed to chronic kidney 
Disease. They had fulgration of the remaining value leaflets prior to 
surgery with no Bladder outlet obstruction. 
One patient had chronic Interstitial Nephritis. One more patients had a 
spinal trauma followed by neurogenic bladder. He required an Ileal 
conduit which was done 3 months prior to the transplantation. 
All the other patients had chronic glomerulo nephritis as judged by the 
presence of proteinuria, borderline size kidneys, Oedema and severe 
hypotension. We were above to do Biopsy in ten o these patients. 
One patient had presented as Rapidly progressive Glomerulo Nephritis 
with renal Biopsy showing crescentic GN. This patient had cytotoxic 
therapy but was dialysis dependent and ultimately had End stage renal 
disease. 
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One patient presented with Nephritic Nephrotic Syndrome and had 
Diffuse Proliferative GN, with crescents on Renal Biopsy. There was a 
rapid progression to ESRD inspite of cytotoxic therapy. 
Two patients had focal segmental glomeruls Sclerosis on initial Biopsy. 
They did not respond to steroid therapy and progressed to ESRD one over 
a period of 5 years and the other over 6 years. 
Six patients had chromic Ig A Nephropathy by renal Biopsy. 
The rest were diagnosed as chromic GN by clinical, biochemical and 
Radiological parameters as outlined above. 
All the Donors were first degree relatives except one of them – who was a 
spousal Donor Tissue typing was done whenever it was available in the 
Hospital. It could not be done for 16 patients and Donors. Authorisation 
Committee approval was obtained for these patients. 
The other 63 patient / Donors underwent tissue typing. None of them had 
nil match 60 patients had Haplomatched Donors and 3 patients had full 
house match. 
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On analysing the Events which took pace in the first year, 43 patients had 
uneventful period. There were 13 patients who had biopsy persons Acute 
Rejection. They were given Pulse-Methyl Prednisolone. 
Four patients ha CMV infection as proved by the presence of B 65 
antigen and Graft Dysfunction. They were treated with Ganciclovir.    
Four patients had Graft dysfunction with evidence of chromic Allograft 
Nephropathy on Renal Biopsy. 
There patients had Urinary tract infection and graft dysfunction due to 
graft pyelonephrits. 
Two patients had high cyclosporine levels with evidence of CNI toxicity 
on Renal Biopsy. 
Ten patients had Graft dysfunction but were not willing for graft biopsy 
due to logistic reasons. They were given pulse Methyl preduisolone with 
a clinical diagnosis of Acute Rejection Graft function at the end of the 
first year was divided into 2 groups. Those patients who had a S-
Creatinine of > 176 μmol/L (2mg/dl) and those who had a S.creatinine of 
≤ 176 μmol/L. 
 48
59 patients our of 79 (84.7%) had S.creatinine levels less than 176 
μmol/L. Out of them 21 had S.Creatinine levels less than 106 μmol/L. 
(26.6%) 
On analysing the variables that affect graft function at 1 year the 
following observations were made: 
1. In the younger Donor age group, a significant number of patients 
had a S.creatinine of less than 176 μmol/L. In a study by Moreso et 
al it was found that patients receiving kidney from an older donor 
and suffer from DGF have a very for long term graft survival . 
2. It was also observed that a good proportion of patients whose 
donors had higher GFR and a S.creatinine level less than 176 
μmol/L. The results were statistically significant by the χ2 and 
student t test. 
3. Merely 50% of those who had Intra operative hypotension, had 
S.creatinine levels >176 μmol/L versus only 28% of those who did 
not have hypotension had high S.creat. These values were not 
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statistically significant due to the small number of patients who had 
intra operative hypotension. 
4. The first day urine output and the time taken to reach normal 
creatinine di not affect the 1 year graft function significantly. 
5. Discharge creatinine was found to have a very good association 
with creatinine at 1 year. Only 15% of those who were discharged 
with normal creatinine had S.creatinine >176 μmol/L at 1 year, 
compared to 58% of those who were discharged with more than 
normal S.creatinine values. This was statistically significant. 
6. The Average S.creatinine at 1 year was significantly different 
between those patients who had an uneventful period and those 
who had Graft dysfunction during that period (first year of 
transplantation). Persons who were diagnosed to have chromic 
Allograft Nephropathy by Biopsy and those persons who had Acute 
Rejection episodes had worst graft functions. Patients with CMV 
Infection or UTI had better graft function. These differences were 
statistically significant. 
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On further analysis by one way ANOVA method, it was found that the 
mean GFR of Donors I patients who had a S.creatinine at 1 year of <176 
μmol/L was 92.90 ml/min ± 12.1 as against 90.20 ml/min ± 14%. 
This was not found to be statistically significant. 
The cold ischaemic time in the two groups were also not different to 
cause statistical significance. 
In these two instances it is important to identify that in this study, the 
Donors are live related where, the GFR is found to be within a normal 
range (since donors having poor GFR are rejected) and also the cold 
Ischaemia time is subsequently short when compared to cadaver Donor 
kidney transplants. 
The age of the recipient, first day output and time to normal creatinine 
were not found to be affecting graft function significantly. 
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The mean age of the donors whose recepients’ creatinine at  1year ≤ 176 
μmol/Lwas 43.12 ± 7.4 years; versus 48.75 ± 7.7 years in those who had 
1 year S.creatinine > 176 μmol/L. This difference was statistically 
significant. 
The mean discharge creatinine was 100.44 ± 20.6 μmol/L in patients 
having 1 year S.creatinine ≤ 176 μmol/L. whereas it was 131.40 ± 66.8 
μmol/L in those who had 1 year S.creatinine of > 176 μmol/L. This 
difference was statistically significant. 
On Multivariate Analysis using Cox regression method, only Donor Age 
was found to be the significant variable affecting graft function at 1 year, 
the P value being 0.004. 
It is probable that younger Donor had better GFR and the mean discharge 
creatinine was lower in those patients who received kidney from younger 
donors. 
 52
CONCLUSIONS 
1. Donor age influenced graft function at 1year significantly. 
2. Discharge creatinine influenced graft function significantly. 
3. Donor GFR was significantly associated with graft function at 1 
year. 
4. Even though Intra operative hypotension had an influence on graft 
function at 1 year, it was not statistically significant. 
5. Events such as Acute Rejections, and Graft Dysfunction during the 
first year significantly influenced graft function at 1 year. 
6. Recipient Age, First day urine output and time taken to reach 
normal creatinine post operatively were not significantly associated 
with graft function at 1 year. 
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LIMITATIONS 
This study had only analysed living Donor transplantations. No 
cadaver transplants wee analysed. 
All patients were given the same Immuno-suppression, making 
comparison between various Immuno-suppression drugs impossible. 
Graft biopsies could not be done and CNI levels could not be tested 
for all patients with graft dysfunction due to logistic reasons. 
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STATISTICAL METHODS 
 
The following Statistical methods were used. 
o Student t’ test 
o Chi square test 
o Analysis of variance by one way ANOVA method 
o Cox regression model for Multivariate analysis. 
o P value of < 0.05 is considered significant. 
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DEFINITIONS 
 
o Normal S.creatinine means a value of S.creatinine less than 106 
μmol/L. 
o Graft Dysfunction means an acute rise in serum creatinine with or 
without decrease in urine output. 
o Acute Rejection has been defined when there is graft dysfunction 
with graft biopsy findings at Acute Rejection. 
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ANNEXURE - I 
Age distribution of Donor and recipient: 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gender distribution among donor and recipients: 
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Sl. 
No: Name
Age Gender NKD DM Bl.Gr D age Gender Rel GFR HLA 
match
CM donor 
BG
Intra-op 
hypo
CIT WIT 1st day 
UO
1st day 
creat
Time to N. 
creat. in 
days
Dis 
creat
3rd mo 
creat
6th mo 
creat
12th mo 
creat
SGF/
DGF CNI tox
Surg 
prob
GDF/AR/AR
T Infections Biopsy
1 prabu 20 M CGN 0 B+ve 55 M F 96 3\6 5% O+ve nil 45 3 8800 396 21 114 149 142 140 SGF Nil nil Nil HCV +ve ND
2 kumar 40 M IG AN 0 AB+ve 58 F M 79 3\6 5% B+ve nil 40 2 16500 246 10 148 156 228 311 SGF Nil nil AR Pulsed UTI I MO AR
3 veeramani 30 M NIL 0 O+ve 35 F S 80 3\6 5% O+ve nil 40 3 12300 184 8 114 130 148 196 N Nil nil GDF nil ND
4 mahesh 27 M IGAN 0 B+ve 54 F M 84 3\6 5% B+ve nil 45 3 5980 237 14 131 144 160 200 SGF Nil nil GDF -CMV CMV +ve Normal
5 divya 19 F NIL 0 O+ve 43 F M 104 3\6 10% O+ve PRESENT 40 1 8300 175 3 88 90 88 88 N Nil nil Nil nil ND
6 venkatesh 31 M FSGS 0 O+ve 50 F M 84 4\6 5% O+ve nil 80 5 14450 102 2 88 95 105 123 N Pos nil Nil can ND
7 murugan 42 M CGN 0 A+ve 51 F S 86 3\6 5% A+ve PRESENT 50 3 5000 254 10 88 88 88 130 DGF Pos nil GDF -CMV CMV +ve ND
8 velusamy 32 M NIL 0 A1+ve 50 F M 98 3\6 10% A+ve nil 40 3 9250 140 7 95 88 114 166 N Nil nil Nil Viral wart ND
9 pandiaraj 17 M NK 0 O+ve 45 F M 88 3\6 10% O+ve nil 40 1 11108 184 2 88 88 140 160 N Nil nil Nil nil ND
10 murugan 27 M NIK 0 B+ve 50 F M 98 3\6 5% B-Ve nil 50 1 15700 108 3 88 88 80 80 N Nil nil Nil nil ND
11 padmanaban 20 M NIL 0 O+ve 50 F M 90 3\6 5% O+ve nil 50 1 10750 108 4 88 88 88 115 N Nil nil Nil nil ND
12 rajan 32 M NIL 0 O+ve 26 F W 88 ND 5% O+ve PRESENT 40 4 12200 96 3 88 88 88 80 N Nil nil Nil Otitis ND
13 dandayuthabani 43 M DN Pr O-ve 55 F S 80 ND 10% O+ve nil 30 3 3070 254 10 105 96 104 103 SGF Pos nil Nil Pulmucor ND
14 bala murugan 20 M NIL 0 B+ve 35 F M 105 3\6 5% B+ve nil 30 3 11000 149 11 90 88 80 156 N Pos nil AR Pulsed Cellulitis AR
15 subburathinam 31 M CGN 0 B+ve 24 F S 110 ND 5% B+ve nil 40 3 11650 175 2 88 96 88 123 N Nil I&D Nil Folliculitis ND
16 balaji 19 M RPGN 0 B+ve 40 M F 82 3\6 10% B+ve nil 50 3 5300 156 2 88 88 90 175 N Pos Nil GDF -CMV nil ND
17 manoharan 51 M NK Pr A+ve 42 M B 78 NIL 5% A+ve PRESENT 35 2 7750 123 8 96 90 96 104 N Nil nil Nil nil ND
18 ezrilarasi 13 F NIK 0 A+ve 35 F M 102 3\6 5% A+ve PRESENT 40 3 2000 262 10 105 96 88 132 SGF Nil LYM Nil nil ND
19 gokulnath 20 M NIK 0 B+ve 45 M F 110 Nil 10% B+ve nil 50 5 1400 490 13 260 306 480 623 DGF Nil GAT CAN nil CAN
20 vivekanandan 32 M CGN 0 A2+ve 55 F M 105 3\6 10% O+ve nil 40 3 7550 210 4 88 88 254 229 N Pos nil AR Pulsed nil AR
21 b.v.baskar 33 M CGN 0 AB-ve 38 F S 45 Nil 5% O+ve nil 40 3 12000 130 10 88 87 96 105 N Nil nil Nil UTI N
22 sasikumar 24 M NIK 0 AB+ve 48 F M 98 Full 10% AB+ve nil 40 3 8000 148 3 88 96 271 134 N Pos nil AR Pulsed PT, HCV AR
23 sukumar 24 M NIK 0 B+ve 30 F S 110 3\6 10% B+ve PRESENT 40 2 9000 96 1 88 131 219 440 N Nil nil GDF -CAN UTI, cellulitis CAN
24 sakthivel 35 M NIK 0 A+ve 56 F M 106 3\6 10% A+ve nil 40 2 16000 100 2 96 150 302 286 N Nil GRA AR Pulsed PT,CMV AR
25 lakshmi 27 F CGN 0 A+ve 50 F M 98 3\6 10% A+ve PRESENT 50 2 14000 118 4 88 120 228 340 N Nil nil GDF -CAN nil Early CAN
26 shiek fareed 26 M NIK 0 B+ve 48 F M 105 3\6 5% B+ve PRESENT 50 3 6300 190 3 99 86 148 131 N Nil nil AR Pulsed CMV, TB ACR
27 govindraj 37 M FSGS 0 B+ve 56 F M 74 3\6 0% B+ve nil 50 4 8750 280 18 104 154 148 140 SGF POS nil Nil HBV, LRI Nil
28 kumari 36 F NIK 0 O+ve 48 F S 76 3\6 5% O+ve nil 50 2 9100 237 12 123 123 208 190 SGF Nil nil Nil HIV, UTI ND
29 kulandaivelu 38 M NIK 0 O+ve 36 M B 102 3\6 10% O+ve nil 40 3 11450 105 2 87 88 140 162 N Pos nil GDF HCV +ve ND
30 m.s.ravi 49 M NIK 0 O+ve 40 M B 103 ND 5% O+ve nil 40 2 10000 148 1 88 88 88 88 N Nil nil Nil nil Normal
31 manikandan 19 M NIK 0 O+ve 45 F M 84 3\6 10% O+ve nil 45 3 6200 131 3 96 123 134 136 N Nil nil Nil nil ND
32 selvaraj 32 M NIK 0 O+ve 55 F M 82 3\6 5% O+ve nil 40 2 7550 96 8 114 148 166 168 N Nil nil AR Pulsed UTI ACR
33 sharmila 25 F NIK 0 B+ve 45 F M 98 3\6 5% B+ve nil 45 3 13350 148 2 88 156 262 146 N Nil nil GDF nil ND
34 suresh 22 M NIK 0 AB+ve 55 F M 72 ND 5% A+ve PRESENT 40 3 13400 131 5 88 140 141 261 N Nil nil GDF-CMV UTI, CMV ND
35 chinna 26 M NIK 0 AB+ve 47 F M 78 4\6 10% B+ve nil 45 3 5200 289 8 114 148 209 140 SGF Nil nil AR Pulsed LRI ND
36 udayakumar 42 M DPGN 0 B+ve 56 M F 74 ND 5% B+ve PRESENT 50 3 12400 131 3 96 343 298 314 N Pos nil GDF nil ND
37 veerapandian 20 M PUV 0 B+ve 40 F M 82 ND 5% B+ve nil 45 3 7200 184 10 148 230 164 148 SGF Nil nil Nil nil ND
38 veeramani 30 M CKD 0 O+ve 35 F S 80 3\6 5% O+ve nil 40 5 12300 184 6 114 166 168 238 N Nil nil AR Pulsed ADD ACR
39 mahesh 22 M CGN 0 B+ve 44 F M 84 4\6 5% B+ve nil 45 3 5900 237 16 131 148 154 132 SGF Pos nil GDF -CMV CMV ND
40 senthil kumar 24 M GN 0 B+ve 45 F M 77 ND 5% O+ve nil 40 3 13700 148 6 85 131 178 134 N Pos nil GDF LRI ND
41 siva kumar 25 M NIL 0 AB+ve 45 F M 94 3\6 10% PRESENT 35 3 8060 210 5 105 146 140 124 N Pos nil GDF nil ND
42 vijayalakshmi 20 F CGN 0 O+ve 55 M F 70 ND 5% O+ve nil 60 3 5750 140 4 105 85 120 240 N Pos nil GDF- CNI nil CNI tox
43 ganesh kumar 41 M NIK 0 B+ve 47 M B 74 6\6 5% B+ve nil 40 3 10500 140 2 96 87 105 110 N Nil nil Nil CMV ND
44 rameshkumar 37 M CGN 0 O+ve 42 F S 104 4\4 5% O+ve nil 35 3 10000 105 3 88 96 105 98 N Nil nil Nil Tonsillitis ND
45 shah nawaz 20 M NIK 0 O+ve 45 F M 89 ND 5% O+ve nil 35 3 11000 356 10 184 140 108 110 SGF Nil nil AR Pulsed UTI ND
46 rajagopal 25 M IGAN 0 O+ve 46 F M 89 5\6 5% O+ve nil 40 3 12300 193 4 123 136 268 234 N Pos nil GDF UTI CNI tox
47 rajesh 22 M CGN 0 B+ve 38 F M 89 5\6 5% O+ve nil 40 3 8400 123 3 96 88 100 86 N Nil nil Nil nil ND
48 arul 30 M Obs. Nep 0 B+ve 47 F M 82 3\6 10% O+ve nil 40 3 9850 140 2 105 115 138 152 N Nil nil Nil RecUTI ND
49 kumar 40 M NIK 0 AB+ve 35 F S 90 3\6 10% AB+ve nil 40 3 11650 88 1 86 85 88 84 N Nil nil Nil CMV ND
50 ayyappan 44 M IGAN 0 B+ve 41 M B 112 3\6 5% O+ve nil 50 3 6600 200 9 114 115 112 103 SGF Nil nil Nil nil ND
Sl. 
No: Name
Age Gender NKD DM Bl.Gr D age Gender Rel GFR HLA 
match
CM donor 
BG
Intra-op 
hypo
CIT WIT 1st day 
UO
1st day 
creat
Time to N. 
creat. in 
days
Dis 
creat
3rd mo 
creat
6th mo 
creat
12th mo 
creat
SGF/
DGF CNI tox
Surg 
prob
GDF/AR/AR
T Infections Biopsy
51 kamaldas 22 M NIK 0 A+ve 26 M B 91 3\6 5% A+ve nil 30 3 15850 96 2 86 105 166 120 N Nil nil Nil PT ND
52 kamala 27 F NIK 0 A1-ve 46 F M 91 3\6 10% A1-ve nil 50 3 10600 184 5 105 97 114 115 N Nil nil Nil nil ND
53 jagadesan 20 M CGN 0 A-ve 50 F M 104 4\6 5% O+ve nil 43 2 14700 123 4 86 96 150 151 N Pos nil GDF nil Normal
54 saravanan 33 M CGN 0 O+ve 27 F S 98 3\6 15% O+ve nil 55 2 6100 184 4 105 96 121 130 N Nil nil Nil nil ND
55 siva kumar 28 M NIK 0 B+ve 50 F M 106 3\6 10% B+ve nil 55 3 11600 105 3 123 281 260 280 N Nil nil GDF -UTI UTI ND
56 komala 28 F NIK 0 O+ve 55 F M 88 4\6 5% O+ve nil 55 2 6200 123 5 96 85 126 175 N Nil nil GDF -UTI UTI ND
57 saravanan 28 M NIK 0 O+ve 46 F M 106 4\6 5% O-ve nil 45 3 19100 153 3 96 113 143 130 N Nil nil Nil HCV+ve ND
58 arunkumar 19 M Obs. Nep 0 B+ve 36 F M 112 3\6 5% O+ve nil 65 3 2500 325 14 146 198 122 119 SGF ATN Nil nil GDF UTI UTI ND
59 vel murugan 13 M PUV 0 A+ve 45 F M 96 3\6 5% A+ve nil 45 2 5150 156 5 88 103 122 124 N Nil nil Nil UTI ND
60 arun 32 M NIK 0 B+ve 54 F M 74 3\6 5% B+ve PRESENT 45 3 850 609 N A 367 265 283 234 SGF Nil nil GDF -CAN nil Early CAN
61 xavier 25 M CGN 0 A1-ve 45 F M 93 3\6 15% A1-ve nil 47 3 11900 155 6 89 103 99 101 N Nil nil Nil nil ND
62 nagaiah 27 M CKD 0 B+ve 32 M B 98 3\6 5% O+ve nil 42 3 8700 108 2 94 100 104 98 N Nil nil Nil nil ND
63 ponnusamy 40 M NIK 0 A+ve 36 F S 88 3\6 5% O+ve nil 60 3 10700 150 7 93 110 144 124 N Nil nil Nil HBV ND
64 shanmugan 46 M NIK 0 A1+ve 40 F S 90 3\6 5% O+ve nil 60 3 4800 144 5 98 134 248 144 N Nil nil AR Pulsed nil ND
65 Buvaneswaran 23 M NK 0 O+ 48 F M 98 3\6 5% O+ve Nil 45 3 8700 235 4 106 98 90 96 N Nil Nil Nil Nil ND
66 Jayanthi 30 F NK 0 B+ 38 M B 116 3\6 5% O+ve Nil 40 3 9600 214 3 98 96 90 88 N Nil Nil Nil Nil ND
67 Rameshkumar 24 M CGN 0 B+ 49 F M 98 3\6 10% B+ve Nil 40 4 7800 245 3 106 88 186 256 N Nil Nil AR Pulsed Nil AR
68 Hemavathy 45 F CIN 0 A+ 50 F S 102 ND 10% A+ve Nil 34 5 8600 196 3 88 86 90 98 N Nil LYM Nil cellulitis ND
69 Perumal 43 M NK 0 O+ 48 F S 98 ND 10% O+ve PRESENT 55 4 3400 342 8 124 116 140 188 SGF Nil Nil Nil Nil ND
70 Ali Baba 23 M CGN 0 AB+ 45 F M 90 3\6 5% B+ve Nil 40 3 8900 230 4 98 90 88 92 N Nil Nl Nil Nil ND
71 Sankar 28 M NK 0 B+ve 50 F M 106 3\6 10% O+ve nil 45 3 10800 105 3 123 281 260 306 N Pos nil GDF nil ND
72 Velu 18 M CGN 0 O+ 47 F M 96 3\6 5% O+ve nil 40 2 5150 150 5 90 103 122 124 N Nil nil Nil nil ND
73 Santhanam 20 M NIK 0 B+ 48 F M 89 ND 5% O+ve nil 35 3 7800 214 5 184 140 108 110 N Nil nil Nil Pneum ND
74 Kumar 25 M CGN 0 A1-ve 45 F M 93 3\6 15% A1-ve nil 45 3 10600 155 6 90 103 99 101 N Nil nil Nil nil ND
75 Suseela 30 F NK 0 B+ 38 M B 116 3\6 5% O+ve Nil 40 3 9600 220 3 98 88 90 90 N Nil Nil Nil Nil ND
76 mani 23 M IgAN 0 AB+ 45 F M 98 3\6 5% B+ve nil 40 5 11800 214 4 90 98 88 88 N Nil Nil Nil UTI ND
77 Raja 25 M IGAN 0 O+ve 46 F M 89 5\6 5% O+ve nil 40 3 12300 193 4 123 136 138 387 N Nil nil AR Pulsed nil AR
78 Raghu 22 M CGN 0 B+ve 38 F M 89 3\6 5% O+ve nil 40 3 8400 123 3 96 88 100 86 N Nil nil Nil nil ND
79 Shanmugam 30 M CGN 0 B+ve 40 F S 104 3\6 10% O+ve nil 40 3 9850 198 4 105 124 154 134 N Pos nil GDF nil ND
